Researchers develop 'nanotrain' for targeted cancer drug transport

April 30, 2013, University of Florida

( —University of Florida researchers have developed a "DNA nanotrain" that fast-tracks its payload of cancer-fighting drugs and bioimaging agents to tumor cells deep within the body. The nanotrain's ability to cost-effectively deliver high doses of drugs to precisely targeted cancers and other medical maladies without leaving behind toxic nano-clutter has been the elusive Holy Grail for scientists studying the teeny-tiny world of DNA nanotechnology.

holds great promise as a new way to deliver chemotherapy directly to cancer cells, but until now, scientists have not been able to direct nanotherapies to consistently differentiate cancer cells from healthy ones. Other limiting factors include high costs, too-small amounts of drugs delivered and potential .

"Most nanotechnology relies on a nanoparticle approach, and the particles are made of ; after they've been used as a carrier for the drug, they'll be left inside the body," said the study's lead investigator, Weihong Tan, a UF distinguished professor of chemistry, professor of physiology and , and a member of the UF Shands Cancer Center and the UF Genetics Institute. "Compared to existing nanostructures, our nanotrain is easier and cheaper to make, is highly specific to cancer cells, has a lot of drug-loading power and is very much biocompatible."

Described in today's issue of the Proceedings of the National Academy of Sciences, Tan's DNA nanotrain is a three-dimensional structure composed of short strands of DNA tethered together into one long train. On the end of the nanotrain is an , a tiny piece of nucleic acid serving as the train's "locomotive" on biochemical autopilot to home in on and bind to specific cancer cells. Trailing behind are tethered that serve as side-by-side, high-capacity "box cars," transporting bioimaging agents or drug cargos to their targets.

"The beauty of the nanotrain is that by using different disease biomarkers you can hitch different types of DNA probes as the train's 'locomotive' to recognize and target different types of cancers," Tan said. "We've precisely targeted leukemia, lung and liver cancer cells, and because the DNA probes are
so precise in targeting only specific types of cancer cells we've seen dramatic reduction in drug toxicity in comparison to standard chemotherapies, which don't discriminate well between cancerous and healthy cells."

Tan and his colleagues report that the DNA nanotrains can be cost-effectively made by mixing bits of DNA in a liquid medium. The mixture is then exposed to a compound that stimulates the pieces of DNA to seek each other out and self-assemble into the DNA nanotrains. The type of cancer cell the DNA nanotrain will seek out and destroy is determined by the specific compound added to the mixture as the trigger.

The study demonstrated in vitro and in mice that the DNA nanotrains exclusively target the cancer cells for which their probes were programmed. The DNA probes go straight to the cancer cells, leading the nanotrains to dock on the cell membranes and gain entry into the cells. Once inside, the drug payloads disperse, killing the cancer cells, a process Tan and his team monitored in real time by measuring the amount of fluorescent light emitted. The biodegradable components of the DNA nanotrains decay with the dead and are removed by the body's normal housekeeping mechanisms.

"Our study found that when loaded with anticancer drugs, these nanotrains inhibited tumor growth in mice more than in those that received drugs injected freely into the bloodstream. What's more exciting is that the mice treated with these nanotrains suffered dramatically fewer side effects than those treated with free drugs," said Guizhi Zhu, a UF doctoral student who was instrumental in the study. "This is what we aim to achieve for future clinical health care of cancer patients."

In addition to longer survival and inhibited tumor growth, the mice that were treated with nanotrain drug delivery experienced less weight loss and are in better condition physically than both the mice that received injected therapy and the mouse control group that received no treatment. Tan and his team attribute these improved outcomes to greatly reduced toxicity achieved by the targeted nanotrain drug delivery.

"We think we have demonstrated that these DNA nanotrains are a promising targeted drug transport platform for delivery of cancer chemotherapeutics with very low toxicity to healthy tissues, and that the platform has wide application for many different cancer types," Tan said. "Moving forward, we are working to identify optimum dosage using mouse models for T-cell leukemia, lung and liver cancers and triple negative breast cancer.

"It's very exciting, but we still have a long way to go before human trials," he said.

Explore further: Molecular detectors may refine cancer treatment

More information: Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics,

Related Stories

Molecular detectors may refine cancer treatment

July 19, 2007

University of Florida researchers have successfully used molecular probes to detect subtle differences in leukemia cells from patient samples, an achievement that could lead to more effective ways to diagnose and treat cancer.

New nanoparticle could improve cancer detection, drug delivery

February 12, 2010

( -- University of Florida scientists have developed a new nanoparticle that could improve cancer detection and drug delivery. The particle, called a 'micelle' and made up of a cluster of molecules called aptamers, ...

Under-twisted DNA origami delivers cancer drugs to tumors

September 13, 2012

Scientists at Karolinska Institutet in Sweden describe in a new study how so-called DNA origami can enhance the effect of certain cytostatics used in the treatment of cancer. With the aid of modern nanotechnology, scientists ...

New drug shrinks cancer in animals, study shows

April 6, 2011

A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

Recommended for you

Quantum dot ring lasers emit colored light

January 22, 2018

Researchers have designed a new type of laser called a quantum dot ring laser that emits red, orange, and green light. The different colors are emitted from different parts of the quantum dot—red from the core, green from ...

Fast computer control for molecular machines

January 19, 2018

Scientists at the Technical University of Munich (TUM) have developed a novel electric propulsion technology for nanorobots. It allows molecular machines to move a hundred thousand times faster than with the biochemical processes ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.